CA2629136C - .alpha.-helix mimetics and method relating to the treatment of cancer stem cells - Google Patents

.alpha.-helix mimetics and method relating to the treatment of cancer stem cells Download PDF

Info

Publication number
CA2629136C
CA2629136C CA2629136A CA2629136A CA2629136C CA 2629136 C CA2629136 C CA 2629136C CA 2629136 A CA2629136 A CA 2629136A CA 2629136 A CA2629136 A CA 2629136A CA 2629136 C CA2629136 C CA 2629136C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
substituted
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2629136A
Other languages
English (en)
French (fr)
Other versions
CA2629136A1 (en
Inventor
Michael Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Choongwae Pharmaceutical Co Ltd
Original Assignee
Choongwae Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharmaceutical Co Ltd filed Critical Choongwae Pharmaceutical Co Ltd
Publication of CA2629136A1 publication Critical patent/CA2629136A1/en
Application granted granted Critical
Publication of CA2629136C publication Critical patent/CA2629136C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2629136A 2005-11-08 2006-11-08 .alpha.-helix mimetics and method relating to the treatment of cancer stem cells Active CA2629136C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73465505P 2005-11-08 2005-11-08
US60/734,655 2005-11-08
PCT/US2006/043859 WO2007056593A2 (en) 2005-11-08 2006-11-08 α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS

Publications (2)

Publication Number Publication Date
CA2629136A1 CA2629136A1 (en) 2007-05-18
CA2629136C true CA2629136C (en) 2016-03-08

Family

ID=37890190

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2629136A Active CA2629136C (en) 2005-11-08 2006-11-08 .alpha.-helix mimetics and method relating to the treatment of cancer stem cells

Country Status (8)

Country Link
US (2) US20070129353A1 (https=)
EP (1) EP1957516B1 (https=)
JP (1) JP5536336B2 (https=)
KR (1) KR101486490B1 (https=)
AU (1) AU2006311433B2 (https=)
CA (1) CA2629136C (https=)
ES (1) ES2570994T3 (https=)
WO (1) WO2007056593A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
JP2009538903A (ja) * 2006-05-30 2009-11-12 チュンウェ ファーマ コーポレーション 幹細胞分化の誘導または抑制のための組成物
WO2008030538A2 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
WO2009061349A1 (en) * 2007-11-05 2009-05-14 Puretech Ventures Methods, kits, and compositions for administering pharmaceutical compounds
WO2009148192A1 (en) 2008-06-06 2009-12-10 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤
US20100022549A1 (en) * 2008-07-23 2010-01-28 The Scripps Research Institute Alpha-helix mimetic with functionalized pyridazine
AU2009286528B2 (en) * 2008-08-29 2014-07-17 Msd Italia S.R.L. Saturated bicyclic heterocyclic derivatives as Smo antagonists
WO2010030948A2 (en) * 2008-09-12 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies
CN102186853A (zh) 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
CN102459271B (zh) * 2009-04-15 2014-07-02 Jw制药公司 回折模拟物的新化合物及其制备方法和用途
US9040531B2 (en) 2009-05-07 2015-05-26 Prism BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CN102906566A (zh) 2010-02-03 2013-01-30 株式会社棱镜生物实验室 与天然变性蛋白质结合的化合物及其筛选方法
WO2011150360A1 (en) 2010-05-28 2011-12-01 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use
CN103209982B (zh) 2010-10-14 2016-03-16 Jw制药公司 反转模拟物的化合物、其制造方法及其用途
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
US20140051706A1 (en) 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto
CN103620024B (zh) 2011-06-09 2016-06-22 弗·哈夫曼-拉罗切有限公司 用于使多能干细胞分化为血管床细胞的方法
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
WO2015056104A2 (en) 2013-10-18 2015-04-23 Hiroyuki Kouji Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
US11213527B2 (en) 2014-03-28 2022-01-04 National University Corporation Tottori University Inhibitory effect of low molecular weight compound on cancer and fibrosis
BR112017027227B1 (pt) * 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
EP3841197A1 (en) 2018-08-21 2021-06-30 F. Hoffmann-La Roche AG Methods for assessing transendothelial barrier integrity
WO2020079107A1 (en) 2018-10-19 2020-04-23 F. Hoffmann-La Roche Ag Synergistic transcription factors to induce high resistance transendothelial barrier
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
CA3194606A1 (en) 2020-10-05 2022-04-14 Fuqiang Ruan Topical agents for dermatological applications
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
AU2002303779A1 (en) * 2001-05-16 2002-11-25 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1444235B1 (en) * 2001-10-12 2008-06-11 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
CA2502644A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
EP1599480B1 (de) * 2003-02-13 2010-06-30 Sanofi-Aventis Deutschland GmbH Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US7390814B2 (en) * 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
EP1660502A2 (en) * 2003-08-28 2006-05-31 Choongwae Pharma Corporation MODULATION OF ß-CATENIN/TCF ACTIVATED TRANSCRIPTION
US7915251B2 (en) * 2005-03-18 2011-03-29 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation

Also Published As

Publication number Publication date
EP1957516A2 (en) 2008-08-20
WO2007056593A2 (en) 2007-05-18
US8293743B2 (en) 2012-10-23
JP5536336B2 (ja) 2014-07-02
AU2006311433B2 (en) 2012-06-28
US20070129353A1 (en) 2007-06-07
US20100069333A1 (en) 2010-03-18
EP1957516B1 (en) 2016-03-09
AU2006311433A1 (en) 2007-05-18
JP2009515890A (ja) 2009-04-16
WO2007056593A3 (en) 2007-07-12
KR101486490B1 (ko) 2015-01-27
ES2570994T3 (es) 2016-05-23
CA2629136A1 (en) 2007-05-18
KR20080070060A (ko) 2008-07-29

Similar Documents

Publication Publication Date Title
CA2629136C (en) .alpha.-helix mimetics and method relating to the treatment of cancer stem cells
JP4387793B2 (ja) 逆向ターンミメティックおよびそれに関連した方法
CA2521846C (en) Reverse-turn mimetics and method relating thereto
CN101827849B (zh) 新型回折模拟物化合物及其用途
KR101257824B1 (ko) 리버스-턴 유사체 및 이와 관련된 방법
US20080171745A1 (en) Methods relating to the treatment of fibrosis
CN101563327A (zh) 嘧啶类激酶抑制剂
AU2002348649A1 (en) Reverse-turn mimetics and method relating thereto
MX2008011837A (es) Compuestos de union al dominio de repeticion de inhibidores de proteinas de apoptosis de baculovirus.
CA2948544A1 (en) Methods for inhibiting necroptosis
JPS63295588A (ja) 生理活性物質ｋ−２５２の誘導体
CZ113692A3 (en) Quinoxalines, process of their preparation and their use
US8324202B2 (en) 5-phenyl-1H-benzo [E] [1,4] diazepine compounds substituted with an hydroxamic acid group as histone deacetylase inhibitors
CN114957219B (zh) 一种靶向降解Gli1蛋白的降解剂及其制备方法和应用
CN115073442B (zh) 含双硫键化合物、及其制法和药物组合物与用途
CN118717739A (zh) 百菌清在制备用于诱导crbn底物泛素化降解的抗肿瘤药物中的应用
HK1234665A1 (en) Methods for inhibiting necroptosis

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240926

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240926

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250929

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250929